Home Alzheimer’s Disease Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements

Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements

In the phase II NRG/RTOG 1122 trial, published in Cancer, the combination of bevacizumab (Avastin) and trebananib was found to be well tolerated; however, it did not significantly improve 6-month progression-free survival (PFS), PFS, or overall survival (OS) for patients with recurrent glioblastoma over bevacizumab alone. 

Additionally, the shorter PFS observed in the experimental arm with a hazard ratio of 1.51 (P = 0.04) suggested that the addition of trebananib to bevacizumab is detrimental.

“Careful consideration should be given to future trials of [angiopoiein; Ang] inhibitors in combination with bevacizumab given the possible detrimental effects of Ang1 in this study,” the authors wrote. “Dual inhibitors of Ang2 and [vascular endothelial growth factor receptor; VEGFR] are in development and may have therapeutic potential for glioblastoma.” 

In this study, patients…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments